MedTrace Logo

Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients

NCT02847403 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-08-17

No results posted yet for this study

Summary

The overall objective of the study is to assess the potential effects of the long-acting GLP-1 analogue exenatide in preventing/slowing the progression of cognitive dysfunction and related biomarkers in dysglycemic/prediabetic patients with mild cognitive impairment (MCI).

Conditions

  • Dysglycemia
  • Cognitive Deficit

Interventions

DRUG

Exenatide

Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.

OTHER

placebo

patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria di Parma

    lead OTHER

Principal Investigators

  • Alessandra Dei Cas, MD · Azienda Ospedaliero-Universitaria di Parma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
51 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-07-31
Completion
2021-10-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02847403 on ClinicalTrials.gov